Search Results - "Biancone L"

Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.

Authors: Biancone, L. Tosti, C. Geremia, A. et al.

Source: Alimentary Pharmacology & Therapeutics. Apr2004, Vol. 19 Issue 7, p755-764. 10p.

Maintenance treatment of Crohn's disease.

Authors: Biancone, L. Tosti, C. Fina, D. et al.

Source: Alimentary Pharmacology & Therapeutics. Jun2003 Supplement 2, Vol. 17, p31-37. 7p.

Monitoring the activity of Crohn's disease.

Authors: Biancone, L. De Nigris, F. Del Vecchio Blanco, G. et al.

Source: Alimentary Pharmacology & Therapeutics. Jul2002 Supplement 4, Vol. 16, p29-33. 5p. 1 Chart.

This result is not displayed to guests.
Login for full access.

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.

Authors: Biancone, L. Orlando, A. Kohn, A. et al.

Source: Gut (0017-5749). Feb2006, Vol. 55 Issue 2, p228-233. 6p.

Technetium-99m–HMPAO Labeled Leukocyte Single Photon Emission Computerized Tomography (SPECT) for Assessing Crohn's Disease Extent and Intestinal Infiltration.

Authors: Biancone, L. Schillaci, O. Capoccetti, F. et al.

Source: American Journal of Gastroenterology (Springer Nature). Feb2005, Vol. 100 Issue 2, p344-354. 11p.

Serum immunomodulatory factors in gastrointestinal diseases. A 30--5-0-kD serum fraction in Crohn's disease capable of modulating lymphocyte activation.

Authors: Biancone, L. Boirivant, M. Fais, S. et al.

Source: Clinical & Experimental Immunology. Mar1991, Vol. 83 Issue 3, p401-406. 6p.

P230 Adalimumab in active ulcerative colitis: A “real-life” observational study

Authors: Armuzzi, A. Biancone, L. Daperno, M. et al.

Source: Journal of Crohn's & Colitis. Feb2012 Supplement 1, Vol. 6, pS101-S101. 1p.

P161 - Newly diagnosed neoplasia in a cohort of Crohn's disease patients treated or untreated with infliximab followed up in the long term: a multicenter matched-pair study

Authors: Biancone, L. Orlando, A. Kohn, A. et al.

Source: Journal of Crohn's & Colitis. Feb2009, Vol. 3 Issue 1, pS74-S74. 1p.

Areas "Indefinite for dysplasia" in Inflammatory Bowel Disease colitis: outcome at subsequent colonoscopy.

Authors: Mancone, R. Neri, B. Fiorillo, M. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1232-i1233. 2p.

Ambulatory Surgery for Perianal Crohn's Disease: Study of Feasibility.

Authors: Sibio, S. Di Giorgio, A. Campanelli, M. et al.

Source: Gastroenterology Research & Practice. 12/23/2018, p1-7. 7p.

Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy.

Authors: Barutta, F. Bellini, S. Kimura, S. et al.

Source: Autophagy. Feb2023, Vol. 19 Issue 2, p505-524. 20p.

Dyspareunia and heavy menstrual bleeding as risk factors for undiagnosed Endometriosis in patients with Inflammatory Bowel Disease: a multidisciplinary prospective study.

Authors: Fiorillo, M. Neri, B. Iacobini, F. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2909-i2909. 1p.

Long-term clinical outcomes in patients with ileo-rectal anastomosis and ileal pouch-anal anastomosis.

Authors: Neri, B. Mancone, R. Distefano, M. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1329-i1329. 1p.

Spontaneous cytotoxicity of intestinal intraepithelial lymphocytes: clues to the mechanism.

Authors: Roberts, A. I. O'connell, S. M. Biancone, L. et al.

Source: Clinical & Experimental Immunology. Dec1993, Vol. 94 Issue 3, p527-532. 6p.

Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.

Authors: Morisco, F. Castiglione, F. Rispo, A. et al.

Source: Journal of Viral Hepatitis. Mar2013, Vol. 20 Issue 3, p200-208. 9p. 6 Charts.

A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease.

Authors: Zorzi, F. Calabrese, E. Monteleone, I. et al.

Source: Alimentary Pharmacology & Therapeutics. Nov2012, Vol. 36 Issue 9, p850-857. 8p. 4 Graphs.

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Authors: Zorzi, F. Zuzzi, S. Onali, S. et al.

Source: Alimentary Pharmacology & Therapeutics. Jun2012, Vol. 35 Issue 12, p1397-1407. 11p. 1 Diagram, 2 Charts, 4 Graphs.

Assessment of cardiovascular risk in waiting-listed renal transplant patients: a single center experience in 558 cases.

Authors: Leonardi, G. Tamagnone, M. Ferro, M. et al.

Source: Clinical Transplantation. Sep/Oct2009, Vol. 23 Issue 5, p653-659. 7p. 1 Diagram, 4 Charts.

Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.

Authors: KOHN, A. DAPERNO, M. ARMUZZI, A. et al.

Source: Alimentary Pharmacology & Therapeutics. Sep2007, Vol. 26 Issue 5, p747-756. 10p. 1 Black and White Photograph, 3 Charts, 3 Graphs.